The FDA granted accelerated approval to Incyte Corporation's (NASDAQ: INCY) Zynyz (retifanlimab-dlwr) for adult patients with metastatic or recurrent locally advanced Merkel cell...
Merck (MRK), known as MSD outside of the United States and Canada, today provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial. KeyVibe-002...
By Davit Kirakosyan Wells Fargo upgraded Amgen (NASDAQ:AMGN) and Eli Lilly (NYSE:LLY) while downgrading Merck (NYSE:MRK). Amgen was upgraded to Overweight from Equal Weight with a...
MDX-2201 leverages ModeX’s innovative biologics platform to target multiple Epstein-Barr virus (EBV) proteinsEBV is the leading cause of infectious mononucleosis and is also...
Two German companies, healthcare company Merck KGaA (DE:MRK) and airline Deutsche Lufthansa (DE:LHA) will report their 2022 earnings this week. Here, we have used the TipRanks...
Merck shares picked up after an upgrade at Wolfe Research. And here is your full Pro Recap of the biggest analyst calls you may have missed on InvestingPro this past week. Start...
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
| Average | 120.81 (+15.28% Upside) |
| High | 155.00 |
| Low | 96.00 |
| Price | 104.80 |
| No. of Analysts | 28 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Neutral | Strong Sell | Buy |
| Technical Indicators | Neutral | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
| Summary | Buy | Strong Buy | Buy | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.16 | 0.17 | 0.16 | 0.00 | 0.00% | 18.86K | Sydney | |||
| 4.81 | 4.87 | 4.81 | -0.080 | -1.64% | 776.24K | Sydney | |||
| 13.51 | 13.69 | 13.28 | +0.16 | +1.20% | 344.83K | Sydney | |||
| 0.185 | 0.195 | 0.183 | 0.00 | 0.00% | 53.09M | Sydney | |||
| 0.135 | 0.14 | 0.13 | +0.005 | +3.85% | 3.67M | Sydney | |||
| 63.42 | 64.00 | 63.32 | -0.37 | -0.58% | 314.64K | Sydney | |||
| 0.001 | 0.001 | 0.001 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.086 | 0.087 | 0.082 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 12.94 | 12.99 | 12.75 | -0.070 | -0.54% | 1.38M | Sydney | |||
| 0.865 | 0.89 | 0.865 | -0.020 | -2.26% | 1.44M | Sydney | |||
| 0.009 | 0.009 | 0.009 | 0.00 | 0.00% | 53.20K | Sydney | |||
| 0.01 | 0.01 | 0.009 | +0.002 | +25.00% | 1.86M | Sydney | |||
| 37.25 | 37.49 | 36.82 | +0.17 | +0.46% | 329.10K | Sydney | |||
| 0.024 | 0.024 | 0.022 | +0.001 | +4.35% | 1.84M | Sydney | |||
| 2.29 | 2.29 | 2.25 | +0.030 | +1.33% | 32.75K | Sydney |